Nephrocare FY26 net loss at ₹80.60 million
Nephrocare Health Services Limited reported a standalone net loss of ₹80.60 million for the financial year ended March 31, 2026, against a net profit of ₹342.36 million in the previous year, while consolidated net profit increased to ₹768.40 million. Revenue from operations grew to ₹6,297.43 million on a standalone basis and ₹9,988.45 million on a consolidated basis. The board approved further investments in overseas subsidiaries and re-appointed M/s. BDO India LLP as Internal Auditor.
*this image is generated using AI for illustrative purposes only.
Nephrocare Health Services Limited has reported its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board, in its meeting held on May 19, 2026, approved the results along with several strategic decisions regarding its overseas subsidiaries.
For the financial year ended March 31, 2026, the company reported a net loss of ₹80.60 million, a significant shift from the net profit of ₹342.36 million recorded in the previous year. Revenue from operations for the year increased to ₹6,297.43 million from ₹5,435.97 million in the prior year. In the quarter ended March 31, 2026, the company returned to profitability with a net profit of ₹108.88 million, compared to a net profit of ₹56.72 million in the corresponding quarter of the previous year.
The board approved a further investment of up to ₹10 crore in Nephrocare Health Services Nepal Private Limited, its wholly owned subsidiary. This investment will be made in one or more tranches towards meeting business operations, working capital requirements, and general corporate purposes. Additionally, the board granted in-principal approval for providing collateral or security support aggregating up to ₹70 crore each to two overseas subsidiaries: Nephrocare Health Services International Pte. Ltd. in Singapore and Nephrocare Health Services Saudi Arabia Company. These guarantees are intended to enable the subsidiaries to avail credit facilities from overseas banks.
The company also re-appointed M/s. BDO India LLP as the Internal Auditor for the financial year 2026-27 based on the recommendations of the Audit Committee. The statutory auditors, M/s. B S R and Co, issued an audit report with an unmodified opinion on the standalone and consolidated financial results.
Standalone Financial Results
The standalone financial performance for the year reflects the impact of non-cash and non-recurring items. The company incurred an interest expense of ₹371.89 million on financial liabilities measured at fair value through profit or loss during the year. Total expenses for the year rose to ₹6,489.46 million from ₹5,138.68 million in the previous year.
| Particulars | Year Ended 31 March 2026 (₹ in Millions) | Year Ended 31 March 2025 (₹ in Millions) |
|---|---|---|
| Revenue from operations | 6,297.43 | 5,435.97 |
| Total income | 6,451.77 | 5,592.28 |
| Total expenses | 6,489.46 | 5,138.68 |
| Profit/(Loss) before tax | (37.69) | 453.60 |
| Net Profit/(Loss) for the year | (80.60) | 342.36 |
Consolidated Financial Results
On a consolidated basis, the group reported a net profit of ₹768.40 million for the year ended March 31, 2026, up from ₹670.96 million in the previous year. Revenue from operations for the group stood at ₹9,988.45 million for the year. The profit for the quarter ended March 31, 2026, was ₹303.70 million.
| Particulars | Year Ended 31 March 2026 (₹ in Millions) | Year Ended 31 March 2025 (₹ in Millions) |
|---|---|---|
| Revenue from operations | 9,988.45 | 7,558.12 |
| Total income | 10,233.58 | 7,699.15 |
| Total expenses | 9,227.91 | 6,824.78 |
| Profit before tax | 974.74 | 874.37 |
| Net Profit for the year | 768.40 | 670.96 |
Historical Stock Returns for Nephrocare Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.77% | +4.15% | +8.00% | +28.91% | +28.91% | +28.91% |
Will the ₹371.89 million interest expense on fair value financial liabilities be a recurring burden in FY2027, and what steps is management taking to restructure or retire these instruments?
How will the ₹70 crore collateral support extended to the Singapore and Saudi Arabia subsidiaries affect Nephrocare's balance sheet risk profile and credit ratings going forward?
Given the strong consolidated revenue growth of over 32% year-on-year, which overseas geographies are driving the most expansion and could additional markets be targeted for entry in the near term?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
